1. Home
  2. NUVL vs ORA Comparison

NUVL vs ORA Comparison

Compare NUVL & ORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVL
  • ORA
  • Stock Information
  • Founded
  • NUVL 2017
  • ORA 1965
  • Country
  • NUVL United States
  • ORA United States
  • Employees
  • NUVL N/A
  • ORA N/A
  • Industry
  • NUVL Biotechnology: Pharmaceutical Preparations
  • ORA Electric Utilities: Central
  • Sector
  • NUVL Health Care
  • ORA Utilities
  • Exchange
  • NUVL Nasdaq
  • ORA Nasdaq
  • Market Cap
  • NUVL 5.8B
  • ORA 5.6B
  • IPO Year
  • NUVL 2021
  • ORA 2004
  • Fundamental
  • Price
  • NUVL $81.76
  • ORA $91.19
  • Analyst Decision
  • NUVL Strong Buy
  • ORA Buy
  • Analyst Count
  • NUVL 11
  • ORA 8
  • Target Price
  • NUVL $120.91
  • ORA $93.38
  • AVG Volume (30 Days)
  • NUVL 429.4K
  • ORA 560.1K
  • Earning Date
  • NUVL 08-07-2025
  • ORA 08-06-2025
  • Dividend Yield
  • NUVL N/A
  • ORA 0.53%
  • EPS Growth
  • NUVL N/A
  • ORA N/A
  • EPS
  • NUVL N/A
  • ORA 2.16
  • Revenue
  • NUVL N/A
  • ORA $906,305,000.00
  • Revenue This Year
  • NUVL N/A
  • ORA $10.25
  • Revenue Next Year
  • NUVL N/A
  • ORA $14.66
  • P/E Ratio
  • NUVL N/A
  • ORA $42.26
  • Revenue Growth
  • NUVL N/A
  • ORA 2.23
  • 52 Week Low
  • NUVL $55.54
  • ORA $61.58
  • 52 Week High
  • NUVL $113.51
  • ORA $95.37
  • Technical
  • Relative Strength Index (RSI)
  • NUVL 64.02
  • ORA 53.21
  • Support Level
  • NUVL $73.28
  • ORA $89.08
  • Resistance Level
  • NUVL $81.10
  • ORA $93.47
  • Average True Range (ATR)
  • NUVL 2.51
  • ORA 1.75
  • MACD
  • NUVL 0.84
  • ORA -0.26
  • Stochastic Oscillator
  • NUVL 92.63
  • ORA 34.02

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About ORA Ormat Technologies Inc.

Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: Electricity Segment. where the company develops, builds, owns and operates geothermal, solar PV and recovered energy-based power plants in the United States and geothermal power plants in other countries and sell the electricity generated. Product Segment includes designing, manufacturing and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement and construction of geothermal and recovered energy-based power plants. Energy Storage Segment includes owning and operating grid-connected which provide capacity, energy and ancillary services directly to the electric grid.

Share on Social Networks: